Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Tolani R, Sathiyaraj S, Lyu D, Truong L, Thurston T, El-Zaatari Z Glomerular Dis. 2025; 5(1):13-18.
PMID: 39991197 PMC: 11842034. DOI: 10.1159/000542859.
References
1.
Kitchlu A, Jhaveri K, Wadhwani S, Deshpande P, Harel Z, Kishibe T
. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep. 2021; 6(1):66-77.
PMC: 7783581.
DOI: 10.1016/j.ekir.2020.10.002.
View
2.
Meraz-Munoz A, Amir E, Ng P, Avila-Casado C, Ragobar C, Chan C
. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020; 8(1).
PMC: 7326260.
DOI: 10.1136/jitc-2019-000467.
View
3.
Ratanasrimetha P, Reddy V, Kala J, Tchakarov A, Glass W, Msaouel P
. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol. 2022; 13:898811.
PMC: 9366044.
DOI: 10.3389/fimmu.2022.898811.
View
4.
Cortazar F, Kibbelaar Z, Glezerman I, Abudayyeh A, Mamlouk O, Motwani S
. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol. 2020; 31(2):435-446.
PMC: 7003302.
DOI: 10.1681/ASN.2019070676.
View
5.
Wakabayashi K, Yamamoto S, Hara S, Okawara M, Teramoto K, Ikeda N
. Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. CEN Case Rep. 2021; 11(2):171-176.
PMC: 9061917.
DOI: 10.1007/s13730-021-00645-3.
View